Ajinomoto hones pharma focus by stepping back from infusions and dialysis
This article was originally published in Scrip
Executive Summary
The wholly owned pharmaceuticals subsidiary of Japan's diversified Ajinomoto group is spinning off its infusion solutions and dialysis product business into a new joint venture to be majority owned by the Japanese generic drug firm Yoshindo.